Jamie Jean Sailors, MS PHD | |
103 Tessie Dr, Jacksons Gap, AL 36861-2522 | |
(334) 728-1336 | |
Not Available |
Full Name | Jamie Jean Sailors |
---|---|
Gender | Female |
Speciality | Marriage & Family Therapist |
Location | 103 Tessie Dr, Jacksons Gap, Alabama |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1992388862 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
106H00000X | Marriage & Family Therapist | 374 (Alabama) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jamie Jean Sailors, MS PHD 103 Tessie Dr, Jacksons Gap, AL 36861-2522 Ph: (334) 728-1336 | Jamie Jean Sailors, MS PHD 103 Tessie Dr, Jacksons Gap, AL 36861-2522 Ph: (334) 728-1336 |
News Archive
New mothers with fibromyalgia (FM) face multiple barriers to breast-feeding their babies, according to a study published recently in the American Journal of Maternal/Child Nursing.
Cellerant Therapeutics Inc., a biotechnology company developing novel hematopoietic stem cell-based cellular and antibody therapies for blood disorders and cancer, announced today that it has signed a contract valued at up to $153 million over five years with the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, to develop CLT-008, a cellular therapy for the treatment of Acute Radiation Syndrome (ARS).
Independent workers - artists, journalists, information technology professionals, craftsmen and even those who earn their living buying and selling on eBay - will soon have the ability to buy health coverage without having to dicker with a privately-run insurance company such as Regence BlueCross BlueShield. ... people can sign up when enrollment opens for the health insurance exchange in October 2013.
Scientists have shown that a brand new type of cancer pill that exploits the emerging field of epigenetics is safe for human use, according to a Phase I trial reported today in Clinical Cancer Research.
PTC Therapeutics, Inc. today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna (ataluren) available to patients before commercial availability in certain countries.
› Verified 9 days ago